Clorox (NYSE:CLX)‘s stock had its “neutral” rating restated by equities researchers at Bank of America in a research report issued on Thursday, Marketbeat.com reports. They currently have a $170.00 target price on the stock, up from their prior target price of $150.00. Bank of America’s price objective would indicate a potential upside of 4.63% from the stock’s previous close.
Other analysts have also recently issued reports about the company. Zacks Investment Research raised Clorox from a “hold” rating to a “buy” rating and set a $171.00 price target for the company in a report on Wednesday, October 3rd. Argus raised Clorox from a “hold” rating to a “buy” rating and set a $175.00 price target for the company in a report on Tuesday, September 25th. ValuEngine raised Clorox from a “hold” rating to a “buy” rating in a report on Saturday, September 22nd. BMO Capital Markets raised their price objective on Clorox from $153.00 to $165.00 and gave the stock a “buy” rating in a research note on Friday, November 2nd. Finally, Barclays set a $131.00 price objective on Clorox and gave the stock a “hold” rating in a research note on Saturday, October 6th. Five equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and three have issued a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus price target of $144.93.
NYSE:CLX opened at $162.47 on Thursday. The company has a market cap of $20.90 billion, a P/E ratio of 25.95, a PEG ratio of 4.02 and a beta of 0.30. The company has a quick ratio of 0.65, a current ratio of 1.07 and a debt-to-equity ratio of 3.38. Clorox has a 1-year low of $113.57 and a 1-year high of $167.70.
In other Clorox news, SVP Diego J. Barral sold 12,880 shares of the firm’s stock in a transaction on Tuesday, November 6th. The stock was sold at an average price of $157.98, for a total transaction of $2,034,782.40. Following the transaction, the senior vice president now owns 18,603 shares in the company, valued at approximately $2,938,901.94. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CEO Benno O. Dorer sold 152,449 shares of the firm’s stock in a transaction on Tuesday, December 4th. The stock was sold at an average price of $164.83, for a total value of $25,128,168.67. Following the transaction, the chief executive officer now owns 111,735 shares in the company, valued at approximately $18,417,280.05. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 265,851 shares of company stock worth $43,238,681. Corporate insiders own 1.40% of the company’s stock.
Several institutional investors and hedge funds have recently modified their holdings of CLX. Csenge Advisory Group bought a new position in shares of Clorox in the 3rd quarter valued at $100,000. Cornerstone Wealth Management LLC bought a new position in shares of Clorox in the 2nd quarter valued at $105,000. Fort L.P. bought a new position in shares of Clorox in the 2nd quarter valued at $129,000. Livingston Group Asset Management CO operating as Southport Capital Management bought a new position in shares of Clorox in the 3rd quarter valued at $130,000. Finally, Ancora Advisors LLC bought a new position in shares of Clorox in the 3rd quarter valued at $135,000. Institutional investors own 77.96% of the company’s stock.
The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Cleaning, Household, Lifestyle, and International. The company offers laundry additives, including bleach products under the Clorox brand, as well as Clorox 2 stain fighter and color booster; home care products primarily under the Clorox, Formula 409, Liquid-Plumr, Pine-Sol, S.O.S, and Tilex brands; naturally derived products under the Green Works brand; and professional cleaning, disinfecting, and food service products under the Clorox, Dispatch, HealthLink, Clorox Healthcare, Hidden Valley, KC Masterpiece, and Soy Vay brands.
Further Reading: What is a Leveraged Buyout (LBO)?
Receive News & Ratings for Clorox Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clorox and related companies with MarketBeat.com's FREE daily email newsletter.